→
Eli Lilly and Co
Eli Lilly's current price of $939.47 reflects a recent decline of 1.65%, yet the company boasts staggering year-over-year EPS growth of 95.89% and revenue growth of 44.70%, indicating strong operational momentum. With a market cap of $887.63B and a ROE of 97.85%, Lilly is well-positioned to capitalize on its innovative GLP-1 product line, especially after launching a new GLP-1 pill that expands access through pharmacy partnerships.
Investors should consider a bullish stance on Eli Lilly given its robust growth prospects and recent product launches.
Eli Lilly vs. Novo Nordisk: The Obesity Drug Race Has a New Leader
2026-04-10
LLY Launches GLP-1 Pill, Expands Access Through Pharmacy Partnerships
2026-04-10
Want AI analysis of your entire portfolio?
Helm Terminal connects to your brokerage, analyzes your holdings, and delivers actionable intelligence weekly.
Get started freeHelm provides financial data for informational purposes only. This is not financial, investment, or tax advice. Consult a qualified professional before making financial decisions.
Helm's AI rates LLY as Bullish. Investors should consider a bullish stance on Eli Lilly given its robust growth prospects and recent product launches.
Despite strong growth metrics, Eli Lilly's high P/E ratio of 43.09 may indicate overvaluation, especially as market sentiments can shift rapidly. Additionally, competitive pressures from companies like Novo Nordisk may hinder Lilly's pricing power and market share in the lucrative obesity treatment market.
Eli Lilly has shown impressive financial results, consistently beating earnings estimates; for instance, in Q4 2025, it reported $7.54 in EPS against an estimate of $6.74. The launch of its GLP-1 pill strengthens its market position, potentially increasing revenue further as it captures greater market share in the obesity drug segment.
Eli Lilly's current price of $939.47 reflects a recent decline of 1.65%, yet the company boasts staggering year-over-year EPS growth of 95.89% and revenue growth of 44.70%, indicating strong operational momentum. With a market cap of $887.63B and a ROE of 97.85%, Lilly is well-positioned to capitalize on its innovative GLP-1 product line, especially after launching a new GLP-1 pill that expands access through pharmacy partnerships.
Eli Lilly's current price of $939.47 reflects a recent decline of 1.65%, yet the company boasts staggering year-over-year EPS growth of 95.89% and revenue growth of 44.70%, indicating strong operational momentum. With a market cap of $887.63B and a ROE of 97.85%, Lilly is well-positioned to capitalize on its innovative GLP-1 product line, especially after launching a new GLP-1 pill that expands access through pharmacy partnerships. Our overall verdict is Bullish.
Helm's analysis is generated by an AI model from live market data. It identifies risk signals, opportunities, and key metrics based on current fundamentals, recent price action, and analyst consensus. It does not execute trades, issue certified investment advice, or predict future prices.
Not financial advice. Informational use only. AI-generated content may contain errors. Consult a licensed financial advisor before making investment decisions. Helm Terminal is not registered as an investment advisor.
Helm Terminal offers free AI-powered stock analysis for LLY at helmterminal.dev/analyze/LLY, updated continuously during US market hours. No signup required.